As policymakers in the U.S. debate strategies to manage high drug costs, officials in Japan have moved to swiftly cut the price on two top-selling cancer meds.Original Article
Japan cuts prices on BMS and Ono’s Opdivo, Merck’s Keytruda: report
You may also like
New alloys for manufacturing freeze-dryers
Navigating the Complexities of Emerging Therapy...
INTERPHEX 2025: Preventing Spills in the Manufacturing...
Agentic AI Growth Predicted, but More Than Half of...
Microsoft and SkyCell Collaborate on Pharma Supply...
Siemens Acquires Dotmatics, Extending AI Software...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.